Cancer Research

A few years ago there was concern that poor people did not have access to the best health care because of high cost, but two new papers find that spending is actually too high.

The first study examines recent trends in spending and use of oral cancer drugs. They find that average spending on the 47 available oral oncolytics — cancer medication taken specifically by mouth — increased from $940 million in the first quarter of 2006 to $1.4 billion by the third quarter of 2011. 


A research group has discovered that AIM - Apoptosis Inhibitor of Macrophage - a protein that plays a preventive role in obesity progression, can also prevent tumor development in mice liver cells. 

This discovery may lead to a therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer and the third most common cause of cancer deaths.


Breast cancer is the second leading cause of cancer death in women, which is why so many medical professionals encourage women to get mammograms. But the tests are not very accurate: only a minority of suspicious mammograms actually leads to a cancer diagnosis.

Bad results lead to needless worry for women and their families—not to mention the time, discomfort and expense of additional tests, including ultrasounds and biopsies. 


Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces clinical trial findings showing that trastuzumab (Herceptin) should remain the standard of care for this cancer.


Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.


Within the first 5 years after the birth of a child, women are considered at an increased risk of developing metastatic breast cancer.

Why that happens has been considered a puzzle but the fact remains that women diagnosed with postpartum breast cancer have a decreased disease free survival time compared to women that have never given birth.

The aggressive tendency of postpartum breast cancer suggests that the post-birth breast environment promotes tumor metastasis. A new study in the Journal of Clinical Investigation, suggests that dying tumor cells in postpartum breast tissue promote metastatic disease.


Ovarian cancer is the most deadly gynecological kind, it claims the lives of more than 50% of women who are diagnosed

Ovarian cancer is often diagnosed late and develops a resistance to chemotherapy but new insight into why may lead to better diagnosis and treatment.


Retinoblastoma is a childhood retinal tumor usually affecting children ages one to two and the most common malignant tumor of the eye in children. Left untreated, retinoblastoma can be fatal or result in blindness.

Retinoblastomas have been found to develop in response to the mutation of a single gene, the RB1 gene, demonstrating that some cells are only a step away from developing into a life-threatening malignancy.


Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort, according to two studies published in  OncoImmunology

Researchers from  at The Ohio State University Comprehensive Cancer Center identify new peptide vaccines and inhibitors that target the HER-3 and IGF-1R receptors. All four agents elicited significant anti-tumor responses in human cancer cell lines and in animal models. 



Head and neck cancer underway. Credit: Akira Kouchiyama, CC BY-SA

By Emma King, University of Southampton and Christian Ottensmeier, University of Southampton